GO
Loading...

On the Line: BioMarin Pharma's CEO Jean Jacques Bienaime

BioMarin Pharmaceuticals should be profitable next year, CEO Jean Jacques Bienaime told Cramer Wednesday on Mad Money, thanks to the expected approval of a new drug.

The drug, Kuvan, has priority-review status with the Food & Drug Administration because of its "advanced medical need," Bienaime said. That means approval could come as soon as November, possibly putting BioMarin in the black for 2008.

Kuvan is a treatment for a metabolic disorder called phenylketonuria. Fifty thousand people eagerly await the drug’s approval because Kuvan will be the first treatment for the disease outside of a rigid diet.

“BMRN is not done going up,” Cramer said.

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

Symbol
Price
 
Change
%Change
BMRN
---

Featured

Contact Mad Money

  • Showtimes

    U.S.
    Monday - Friday 6p ET
    Australia
    Saturday 8a, 1p, 7p SYD
    Sunday 12a, 1a, 8a, 7p SYD
    New Zealand
    Saturday 10a, 3p, 9p NZ
    Sunday 2a, 3a, 10a, 9p NZ
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.